Email the author Effects of Ginseng Extract to The Plasma Level of Interleukin-8, COPD Assessment Test Scores, and Length of Hospitalization Acute Exacerbation of COPD Patients
Abstract
Method: This study aimed to analyze the effect of ginseng extract on plasma levels of IL-8, CAT scores, and length of hospitalization of patients with COPD exacerbations. Clinical trials of experimental with pre test and post test design was conducted on 34 patients with COPD exacerbation in Dr. Moewardi Hospital Surakarta and Dr. Ario Wirawan Lung Hospital Salatiga from August until September 2016. Samples were taken by consecutive sampling were divided into two groups. The treatment group (n = 17) received standard therapy and ginseng extracts 2x100mg/day and the control group received only standard therapy (n = 17). Clinical improvement measured in CAT score and length of stay. Plasma levels of IL-8, CAT scores, and longer hospitalization time measured at entry and discharge criteria are met. Length of stay based on the number of days of care in hospitals.
Results: There were significant difference (p=0.000) towards decreased of of IL-8 plasma level between treatment group (-12.38 ± 10,35pg/ml) and control group (0.65 ± 7,92pg/ml), towards decrease of CAT score (p=0.000) between treatment group (-16.53 ± 1.28) and control group (-12.59 ± 2.87), and length of stay (p = 0.004) between treatment group (4.29 ± 1.45) and control group (5.76 ± 1.20).
Conclusions: The addition of ginseng extract 2x100 mg/day during hospitalization was significantly lowered plasma levels of IL-8, CAT scores, and shortening the length of stay. (J Respir Indo. 2018; 38: 192-8)
Keywords
Full Text:
PDFReferences
Bhandari R, Sharma R. Epidemiology of chronic obstructive pulmonary disease: a descriptive study in the mid-western region of Nepal. International Journal of COPD. 2012;27:253-7
Viet NN, Yunus F, Phuong AN, Bich VD, Damayanti T, Wiyono WH. The prevalence and patient characteristics of chronic obstructive pulmonary disease in non-smokers in Vietnam and Indonesia: an observational survey. Respirology. 2015;20:602-11
Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. United States of America: Global Initiative for Chronic Obstructive Lung Disease Inc;2016
White AJ, Gompertz S, Stockley RA. Chronic obstructive pulmonary disease: The etiology of exacerbations of chronic obstructive pulmonary disease. Thorax. 2003;58:73-80
Bahadory K, Fitzgerald JM, Levy RD, Fera T, Switson J. Risk factors and outcomes associated with chronic obstructive pulmonary disease excacerbations requiring hospitalization. Can Respir J. 2009;16:643-9
Goshal AG, Dhar R, Kundu S. Treatment of acute exacerbation of COPD. Supplement To Japi. 2012;60:38-43
Shapiro SD, Reilly JJ, Rennard SI. Chronic bronchitis and emphysema. In: Mason RJ, Murray JF, Broaddus VC, Nadel JA, editors. Murray and Nadel’s textbook of respiratory medicine. 5th ed. Philadelphia: Elsevier Inc; 2010.p.919-55
Perhimpunan Dokter Paru Indonesia. Penyakit Paru Obstruktif Kronik. Diagnosis dan Penatalaksanaan. Jakarta: Perhimpunan Dokter Paru Indonesia; 2011.p.1-88
Mukaida N. Pathophysiological roles of interleukin-8/CXCL8 in pulmonary disease. Am J Physiol Cell Mol Physiol. 2003;284:566-77
Tanino M, Betsuyaku T, Takeyabu K. Increased levels of interleukin-8 in BAL fluid from smokers suceptible to pulmonary emphysema. Thorax. 2002;57:405-11
Sethi S, Malla P, Jhonston SL. New paradigms in the pathogenesis of chronic obstructive pulmonary disease II. Proc Am Thorac Sec. 2009;6:532-4
Senior RM, Atkinson JJ. Chronic obstructive pulmonary disease: Epidemiology, pathophysiology and pathogenesis. In: Fishman AP, Elias AP, Fishman JA, Grippi MA, Senior RM, Pack AI, editors. Fishman’s pulmonary disease and disorders. 4th ed. USA: McGraw-Hill company Inc; 2008.p.707-27
Rovina N. The role of vascular endotehlial growth factor in the pathogensis of chronic obstructive pulmonary disease. Pneumon. 2008;21:68-76
Barnes PJ, Stockley RA. COPD: Current therapeutic interventions and future approaches. Eur Respir J. 2006;25:1084-6
Mackay AJ, Donaldson GC, Patel AR, Jones PW, Hurst JR. Usefulness of The Chronic Obstructive Pulmonary Disease Assessment Test to Evaluate Severity of COPD Excacerbations. American Journal Respiratory Critical Care Medicine. 2012;185:1218-24
Alexandre BM, Penque D. Chronic obstructive pulmonary disease and proteomics: a match for success?. J Aller Ther. 2012;87:1-6
Park J, Cho JY. Antiinflammatory effects of ginsenosides from panax ginseng and their structural analogs. African Journal of Biotechnology. 2009;8:3682-90
Shergis JL. Panax ginseng for chronic obstructive pulmonary disease (COPD). 2013. Thesis. Requirement for the degree of doctor of philosophy. School of Health Sciences RMIT University. Melbourne
Chai H, Wang Q, Huang L, Xie T, Fu Y. Ginsenoside Rb1 Inhibited Tumor Necrosis Factor-α Induced Vascular Cell Adhesion Molecule-1 Expression in Human Endothelial Cells. Biological & Pharmaceutical Bulletin. 2008;32:2050-6
Hofseth LJ, Wargovich MJ. Inflammation, cancer, and targets of ginseng. American Society for Nutrition. 2007;137:183-5S
DOI: https://doi.org/10.36497/jri.v38i4.20
Refbacks
- There are currently no refbacks.
Copyright (c) 2018 Jurnal Respirologi Indonesia
INDEXING & PARTNER
| Jurnal Respirologi Indonesia pISSN: 0853-7704 - eISSN: 2620-3162 Address: Jalan Cipinang Bunder No. 19, Cipinang, Pulogadung, Jakarta Timur, DKI Jakarta 13240, Indonesia Phone: +62-21-2247-4845 Email: editor@jurnalrespirologi.org |  An official publication by the Indonesian Society of Respirology (ISR) |
 Creative Commons Attribution-NonCommercial 4.0 International License Statcounter |